All In Biotech

Drug Trial Radar · NCT03974113

Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

ATLAS-PEDS: An Open-label, Multinational Study of Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

32

Actual

Start

Jan 28, 2020

Primary completion

Aug 4, 2026

Study completion Aug 4, 2026

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Jun 4, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 1 year, up to 11 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: \- To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to \<12 years of age) with severe hemophilia A or B Secondary Objectives: * To characterize the safety and tolerability * To determine fitusiran plasma concentrations at selected time points

Conditions

  • Hemophilia

Interventions

  • FitusiranDrug

    Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Plasma antithrombin (AT) activity levelsTime frame: Day 1 to the AT analysis time point at the optimal therapeutic dose (approximately 256 weeks)

Locations

16 sites in 6 countries. Site status is shown where the registry gives one.

  • Children's Hospital Los Angeles Site Number : 8400002

    Los Angeles, California

  • Hackensack University Medical Center- Site Number : 8400008

    Hackensack, New Jersey

  • University Hospitals of Cleveland- Site Number : 8400007

    Cleveland, Ohio

  • Penn State Milton S. Hershey Medical Center- Site Number : 8400006

    Hershey, Pennsylvania

  • Investigational Site Number : 1240001

    Hamilton, Ontario, Canada

  • Investigational Site Number : 1240002

    Ottawa, Ontario, Canada

  • Investigational Site Number : 3560006

    Bangalore, India

  • Investigational Site Number : 3560002

    Mumbai, India

  • Investigational Site Number : 3560001

    Pune-411011, India

  • Investigational Site Number : 3560004

    Vellore, India

  • Investigational Site Number : 3800002

    Florence, Italy

  • Investigational Site Number : 3800001

    Milan, Italy

  • Investigational Site Number : 7240002

    Madrid, Madrid, Comunidad de, Spain

  • Investigational Site Number : 7920001

    Adana, Turkey (Türkiye)

  • Investigational Site Number : 7920002

    Istanbul, Turkey (Türkiye)

  • Investigational Site Number : 7920003

    Izmir, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.